MicroPort NeuroScientific's (HKG:2172) subsidiary, MicroPort NeuroTech (Shanghai), received U.S. Food and Drug Administration approval to market the Numen Helia Coil Embolization System, according to a Monday Hong Kong bourse filing.
Shares of the medical device company fell nearly 1% in Tuesday morning trade.
The device is designed to obstruct or occlude blood flow in vascular abnormalities of neurovascular vessels through endovascular procedures, the filing said.
Chuangxin Industries (HKG:2788) said its unit Inner Mongolia Chuangyuan Metal may be liable to pay 400 million yuan to 500 million yuan in taxes as it undergoes a so-called tax guidance because of its inclusion in the preferential tax policy for high-tech enterprises, according to a filing with the Hong Kong bourse Monday.The aluminum company's shares fell over 4% in morning trade Tuesday.Chuangxin Industries said it has sufficient cash and bank deposits to cover the potential tax payment and the issue is not expected to have any material adverse effect on the group's overall financial condition.
Bank of Communications (SHA:601328, HKG:3328) completed the issuance of 40 billion yuan of its tier 1 capital bonds on Monday, according to a Tuesday filing with the Shanghai Stock Exchange.The bonds have a coupon of 1.94% for the first five years, adjustable every five years, with a conditional redemption option on each interest payment date from year 5 onwards, the bank said.
Atlas Arteria's (ASX:ALX) independent directors urged its security holders in its target's statement to reject an unsolicited off-market cash takeover offer by Diamond Infraco 1, a wholly-owned unit of IFM Global Infrastructure Fund, saying "it is opportunistic and materially undervalues Atlas Arteria," according to a Tuesday Australian bourse filing.The directors' view was reinforced by the opinion of an independent expert, who concluded that the offer is neither fair nor reasonable.The target's statement was sent to Diamond Infraco and lodged with the Australian Securities and Investments Commission on Tuesday. The bidder offered the security holders AU$4.75 in cash per ALX Atlas Arteria security, less any distributions paid by the firm.Diamond Infraco expressed "strong disagreement" with the arguments brought forth by the independent directors of Atlas Arteria to support their recommendation that Atlas Arteria security holders reject the offer, according to its second supplementary bidder's statement.It confirmed that the EU merger control regulatory approval condition, as stated in the bidder's statement, was satisfied.